Shots:

• The P-III JAVELIN Bladder 100 study involves assessing of Bavencio + best supportive care (BSC) vs BSC monothx in 700 patients with LA or mUC whose disease did not progress after completion of 1L Pt-chemotherapy
• The study resulted in improvement in OS with consistent safety results and will be shared with the US FDA and multiple regulatory bodies. In 2017- the US FDA approved Bavencio under accelerated approval for LA or mUC who have disease progression during or following Pt-CT- or who have disease progression within 12 mos. of neoadjuvant or adjuvant treatment with PT-CT
• Bavencio (avelumab) is an anti-PD-L1 Ab that blocks the interaction of PD-L1 with PD-1 receptors. In Nov 2014- Merck and Pfizer collaborated to co-develop and co-commercialize Bavencio

Click here to read full press release/ article | Ref: Pfizer | Image: CHE Manager